Natera Surges Into Top 250 Actives on 48.47% Trading Volume Spike Following Fetal Focus Launch

On August 7, 2025, Natera (NASDAQ: NTRA) saw its stock rise 2.14% with a trading volume of $460 million, a 48.47% increase from the prior day. This performance placed it among the top 250 most actively traded stocks. The move followed the company’s launch of Fetal Focus, a noninvasive prenatal test designed to detect inherited conditions in fetuses when the biological father is unavailable for testing.

Fetal Focus targets five genes linked to severe conditions, including cystic fibrosis and sickle cell disease. The test leverages Natera’s proprietary LinkedSNP™ technology to identify homozygous variants, a technically challenging detection scenario. Clinical data from the EXPAND trial, a blinded study involving 1,300 participants, showed 91% sensitivity in its first milestone readout, with successful identification of all five fetuses with homozygous mutations. The trial’s diverse population and rigorous validation align with Natera’s emphasis on robust clinical evidence.

John Williams, principal investigator for EXPAND, highlighted the test’s role in enabling informed decision-making during pregnancy. Sheetal Parmar, Natera’s senior vice president, noted that Fetal Focus expands the company’s reproductive health portfolio by addressing unmet clinical needs. The product’s integration with Natera’s existing Horizon carrier screen further strengthens its value proposition in a competitive diagnostic market.

The strategy of purchasing the top 500 stocks by daily trading volume and holding them for one day delivered a 166.71% return from 2022 to the present, outperforming the benchmark return of 29.18% by 137.53%. This underscores the role of liquidity concentration in short-term stock performance, particularly in volatile markets.